Brief: Coya Therapeutics To Present ALS Clinical Study Data At 2023 MDA Conference
27/02/2023 12:11
Feb 27 (Reuters) - Coya Therapeutics Inc COYA.O :
* COYA THERAPEUTICS TO PRESENT ALS CLINICAL STUDY DATA
FOR ITS
INVESTIGATIONAL BIOLOGIC COMBINATION AT THE 2023 MUSCULAR
DYSTROPHY ASSOCIATION (MDA) CLINICAL & SCIENTIFIC CONFERENCE
Source text for Eikon: ID:nBw9HxdsYa
Further company coverage: COYA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Coya Therapeutics
See all newsCoya Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Coya Therapeutics Q2 net loss widens as R&D costs rise
Coya Therapeutics Inc expected to post a loss of 34 cents a share - Earnings Preview
Brief: Coya Therapeutics Entered Into Sales Agreement, May Offer And Sell From Time To Time Shares Of Co's Common Stock For Up To $30 Million
Brief: Coya Therapeutics Has Been Granted U.S. FDA Fast Track Designation For Coya 302 For The Treatment Of Amyotrophic Lateral Sclerosis (ALS)